Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Fujian Aonong Biological Technology Grouporp EBITDA Margin % Related Terms
Fujian Aonong Biological Technology Grouporp EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603363 vs ADM, BG, TSN: EBITDA Margin % Comparison
For the Farm Products subindustry, Fujian Aonong Biological Technology Grouporp's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fujian Aonong Biological Technology Grouporp EBITDA Margin % vs Consumer Packaged Goods Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fujian Aonong Biological Technology Grouporp (SHSE:603363) has a EBITDA Margin % of -0.57% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Fujian Aonong Biological Technology Grouporp and its competitors. According to the industry distribution chart, Fujian Aonong Biological Technology Grouporp ranks #1624 out of 1958 companies in the Consumer Packaged Goods industry, placing it in the top 82.9%.
Is Fujian Aonong Biological Technology Grouporp's EBITDA Margin % too high?
Fujian Aonong Biological Technology Grouporp's current EBITDA Margin % is -0.57%. Based on the distribution chart, Fujian Aonong Biological Technology Grouporp ranks #1624 out of 1958 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Fujian Aonong Biological Technology Grouporp has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fujian Aonong Biological Technology Grouporp's EBITDA Margin % compare to ADM and BG?
According to the Consumer Packaged Goods industry distribution chart, Fujian Aonong Biological Technology Grouporp ranks #1624 out of 1958 companies for EBITDA Margin %. This places Fujian Aonong Biological Technology Grouporp in the lower half of its industry. The industry median EBITDA Margin % is 8.98. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Consumer Packaged Goods company?
The median EBITDA Margin % among Consumer Packaged Goods companies is 8.98, based on 1,958 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Fujian Aonong Biological Technology Grouporp and its competitors. For the Consumer Packaged Goods industry, the median EBITDA Margin % is 8.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fujian Aonong Biological Technology Grouporp's current EBITDA Margin % is -0.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fujian Aonong Biological Technology Grouporp stock overvalued right now?
Based on GuruFocus' analysis, Fujian Aonong Biological Technology Grouporp (SHSE:603363) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥1.32, compared to a current price of ¥2.67 — trading 102.3% above its estimated fair value. The current EBITDA Margin % is -0.57%. Fujian Aonong Biological Technology Grouporp's overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Fujian Aonong Biological Technology Grouporp (SHSE:603363), the current EBITDA Margin % is -0.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fujian Aonong Biological Technology Grouporp (SHSE:603363) Overvalued in 2026?
Based on GuruFocus' analysis, Fujian Aonong Biological Technology Grouporp stock appears to be overvalued.
The current stock price of ¥2.67 is trading 102.3% above its estimated GF Value™ of ¥1.32.
GuruFocus considers Fujian Aonong Biological Technology Grouporp to be Significantly Overvalued.
Key valuation signals for SHSE:603363:
EBITDA Margin %: -0.57%
GF Value™: ¥1.32 vs. price of ¥2.67 (102.3% above fair value)
No single metric tells the full story. See the SHSE:603363 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fujian Aonong Biological Technology Grouporp Business Description
Fujian Aonong Biological Technology Group Incorp Ltd is an agricultural and animal husbandry enterprise in China. The principal business activities of the company include feed-oriented service, animal protection, pig raising, and raw material trade. In addition, the company's insurance business mainly relies on the feed marketing system throughout the country to provide downstream farmers with relevant products for disease prevention and control.
31GF Score
Get the complete analysis for SHSE:603363
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603363 has been successfully added to your 
